66372 Federal Register / Vol. 62, No. 243 / Thursday, December 18, 1997 / Notices

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than January 12,

1998.

A. Federal Reserve Bank of

Richmond (A. Linwood Gill III,

Assistant Vice President) 701 East Byrd

Street, Richmond, Virginia 23261-4528:

1. Shore Financial Corporation,

Onley, Virginia; to become a bank

holding company by acquiring 100

percent of the voting shares of Shore

Bank, Onley, Virginia.

B. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411

Locust Street, St. Louis, Missouri 63102-

2034:

1. First United Bancshares, Inc., El

Dorado, Arkansas; to merge with

Citizens National Bancshares of Hope,

Inc., Hope, Arkansas, and thereby

indirectly acquire Citizens National

Bank of Hope, Hope, Arkansas, and

Peoples Bank and Loan Company,

Lewisville, Arkansas.

C. Federal Reserve Bank of Kansas

City (D. Michael Manies, Assistant Vice

President) 925 Grand Avenue, Kansas

City, Missouri 64198-0001:

1. FNB Financial Services, Inc. ESOP,

Durant, Oklahoma; to acquire .3 percent

of the voting shares of FNB Financial

Services, Inc., Durant, Oklahoma, and

thereby indirectly acquire The First

National Bank in Durant, Durant,

Oklahoma.

Board of Governors of the Federal Reserve

System, December 15, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–33087 Filed 12–17–97; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in

Permissible Nonbanking Activities or

to Acquire Companies that are

Engaged in Permissible Nonbanking

Activities

The companies listed in this notice

have given notice under section 4 of the

Bank Holding Company Act (12 U.S.C.

1843) (BHC Act) and Regulation Y, (12

CFR Part 225) to engage de novo, or to

acquire or control voting securities or

assets of a company that engages either

directly or through a subsidiary or other

company, in a nonbanking activity that

is listed in § 225.28 of Regulation Y (12

CFR 225.28) or that the Board has

determined by Order to be closely

related to banking and permissible for

bank holding companies. Unless

otherwise noted, these activities will be

conducted throughout the United States.

Each notice is available for inspection

at the Federal Reserve Bank indicated.

The notice also will be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether the proposal complies

with the standards of section 4 of the

BHC Act.

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than January 2, 1998.

A. Federal Reserve Bank of Kansas

City (D. Michael Manies, Assistant Vice

President) 925 Grand Avenue, Kansas

City, Missouri 64198-0001:

1. Gold Banc Corporation, Inc.,

Leawood, Kansas; to acquire Midwest

Capital Management, Inc., Kansas City,

Missouri, and thereby indirectly engage

in financial and investment advisory

activities, pursuant to § 225.28(b)(6) of

the Board’s Regulation Y; agency

transactional services for customer

investments including securities

brokerage, riskless principal

transactions and private placement

services, pursuant to §§ 225.28(b)(7)(i),

(ii), and (iii) of the Board’s Regulation

Y; investment transactions as principal,

including underwriting and dealing in

government obligations and money

market instruments, pursuant to §

225.28(b)(8)(i) of the Board’s Regulation

Y; investing and trading activities, i.e.

engaging as principal in financial

futures, pursuant to § 225.28(b)(8)(ii)(B)

of the Board’s Regulation Y; providing

management consulting advice,

pursuant to § 225.28(b)(9)(A) of the

Board’s Regulation Y.

Board of Governors of the Federal Reserve

System, December 15, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–33086 Filed 12–17–97; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

has made a final finding of scientific

misconduct in the following case:

S. Ashraf Imam, Ph.D., University of

Southern California: Based on an

investigation report forwarded to the

Office of Research Integrity (ORI) by the

University of Southern California (USC)

as well as information obtained by ORI

during its oversight review, ORI found

that Dr. Imam, an Associate Professor in

the Department of Pathology, USC,

engaged in scientific misconduct by

including plagiarized material in a grant

application submitted to the National

Cancer Institute (NCI), National

Institutes of Health (NIH).

Specifically, Dr. Imam’s NIH grant

application contained extensive

paraphrasing of the text of another

researcher’s independent grant

application to a state agency. Dr. Imam

had been given that application by a

colleague in confidence. The colleague

was a reviewer on the state grant

application and requested that Dr. Imam

evaluate it and return the application to

him.

The other researcher’s application

was subsequently funded. Dr. Imam

paraphrased or copied into his NIH

application all of the other researcher’s

specific aims, the background on

proposed methods, the experimental

design and research plan, and most of

the references; only the preliminary

results sections of Dr. Imam’s

application were different.

Dr. Imam has accepted the ORI

finding and has entered into a Voluntary

Exclusion Agreement with ORI in which

he has agreed, for the three (3) year

period beginning December 8, 1997, to

exclude himself voluntarily from:

(1) any contracting or subcontracting

with any agency of the United States

Government and from eligibility for, or

involvement in, nonprocurement

transactions (e.g., grants and cooperative

agreements) of the United States

Government as defined in 45 CFR Part

76 (Debarment Regulations); and

(2) serving in any advisory capacity to

the Public Health Service (PHS),

including but not limited to service on

any PHS advisory committee, board,

and/or peer review committee, or as a

consultant.

No scientific publications were

required to be corrected as part of this

Agreement.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research
Federal Register / Vol. 62, No. 243 / Thursday, December 18, 1997 / Notices 66373

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal, J.D.,

Acting Director, Office of Research Integrity.

[FR Doc. 97–33035 Filed 12–17–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration for Children and

Families

Proposed Information Collection

Activity; Comment Request, Proposed

Projects

Title: IRS Project 1099.

OMB No.: New Collection.

Description: A voluntary program

which provides States’ Child Support

Enforcement agencies upon there

request access to all of the earned and

unearned income information reported

to IRS by employers and financial

institutions. The IRS 1099 information

is used to locate noncustodial parents

and to verify income and employment,

which has proven essential to accurately

establishing and enforcing child support

obligations.

Respondents: State, Local, or Tribal

Govt.

ANNUAL BURDEN ESTIMATES

Instrument Number of respondents

Number of responses per

respondent

Average burden hours per

response

Total burden

hours

OCSE 1099 Request Records ......................................................................... 43 12 1 1,032

Estimated Total Annual Burden

Hours: 1,032.

In compliance with the requirements

of Section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Administration for Children and

Families is soliciting public comment

on the specific aspects of the

information collection described above.

Copies of the proposed collection of

information can be obtained and

comments may be forwarded by writing

to the Administration for Children and

Families, Office of Information Services,

Division of Information Resource

Management Services, 370 L’Enfant

Promenade, S.W., Washington, D.C.

20447, Attn: ACF Reports Clearance

Officer. All requests should be

identified by the title of the information

collection.

The Department specifically requests

comments on: (a) Whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency, including

whether the information shall have

practical utility; (b) the accuracy of the

agency’s estimate of the burden of the

proposed collection of information; (c)

the quality, utility, and clarity of the

information to be collected; and (d)

ways to minimize the burden of the

collection of information on

respondents, including through the use

of automated collection techniques or

other forms of information technology.

Consideration will be given to

comments and suggestions submitted

within 60 days of this publication.

Dated: December 15, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–33083 Filed 12–17–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0517]

Changes in Medical Device Tracking

and Postmarket Surveillance Authority

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice of meeting.

The Food and Drug Administration

(FDA) is announcing the following

meeting: Changes in medical device

tracking and postmarket surveillance

authority under the Food and Drug

Administration Modernization Act of

1997. The topic to be discussed is

postmarket controls, including tracking

and/or surveillance of devices.

Date and Time: The meeting will be

held on January 15, 1998, 9 a.m. to 3

p.m.

Location: The meeting will be held at

the University of Maryland Auditorium,

9640 Gudelsky Dr., Rockville, MD.

Contact: Casper E. Uldriks, Center for

Devices and Radiological Health (HFZ–

300), Food and Drug Administration,

2098 Gaither Rd., Rockville, MD 20850,

301–594–4692, FAX 301–594–4610.

Registration and Requests for Oral

Presentations: Send registration

information (including name, title, firm

name, address, telephone, and fax

number) and written material and

requests to make oral presentations to

the contact person by January 5, 1998.

Written comments may be submitted to

the Dockets Management Branch (HFA–

305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1–23,

Rockville, MD 20857, by January 5,

1998.

If you need special accommodations

due to a disability, please contact

Casper E. Uldriks at least 7 days in

advance of the meeting.

Transcripts: Transcripts of the

meeting may be requested in writing

from the Freedom of Information Office

(HFI–35), Food and Drug

Administration, 5600 Fishers Lane, rm.

12A–16, Rockville, MD 20857,

approximately 15 working days after the

meeting at a cost of 10 cents per page.

The agency is interested in discussing

the statutory changes concerning

tracking and postmarket surveillance

under the Food and Drug

Administration Modernization Act of

1997 and whether the agency should

develop additional criteria to use to

determine whether tracking or

postmarket surveillance requirements

should be ordered by FDA. The agency

would like to supplement the statutory

criteria with additional nonbinding

criteria to help determine which devices

may need to be added or removed from

the list of devices subject to tracking

and/or postmarket surveillance

requirements. FDA intends to publish

its revised lists by February 19, 1998,

the effective date of the new law.

By way of example, additional criteria

that would support a tracking order

might include the likelihood of a recall,

or the likelihood of irreversible clinical

outcomes. Additional criteria that might

not support a tracking order, for

example, might include current,

standard clinical practices that mitigate

risk. Additional criteria that would

support a postmarket surveillance order

might include, for example, the use of

a new technology or the need to assess

a new public health issue based on

measurable outcomes. Additional

criteria that would not support a